<DOC>
	<DOCNO>NCT00464893</DOCNO>
	<brief_summary>Primary evaluation safety , tolerability feasibility regard specific postoperative complication adjuvant treatment catumaxomab administer curative tumor resection subsequent neoadjuvant chemotherapy .</brief_summary>
	<brief_title>Phase II Study With Catumaxomab Patients With Gastric Cancer After Neoadjuvant CTx Curative Resection</brief_title>
	<detailed_description>An open-label , multi-center phase II study surgically resectable patient neoadjuvant ECX-chemotherapy , confirm diagnosis gastric adenocarcinoma high risk disseminate tumor cell due serosal infiltration positive lymph node curative gastrectomy . Treatment catumaxomab consist initial dose 10 µg give intraoperatively intraperitoneal bolus four postoperative ascend dos ( 10-20-50-150 µg ) administer i.p.-infusion use installed abdominal i.p.-port postoperative day 7 , 10 , 13 16 . Catumaxomab trifunctional antibody target EpCAM tumor cell CD3 T cell . Trifunctional antibody represent new concept target anticancer therapy . This new antibody class capability redirect T cell accessory cell ( e.g . macrophage , dendritic cell [ DCs ] natural killer [ NK ] cell ) tumor site . According preclinical data , trifunctional antibody activate different immune effector cell , trigger complex anti-tumor immune response .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>sign date informed consent male female patient age 18 year old patient primary diagnosis histologically confirm gastric adenocarcinoma ( include GE junction SiewertType 2 3 ) TNMstaging screen T3/T4 , N+/ , M0 T2 , N+ , M0 indication eligibility neoadjuvant chemotherapeutic regimen feature three cycle ECX 21 day per cycle intend curative gastrectomy Karnofsky index &gt; 70 Exposure prior cancer therapy plan adjuvant chemo radiotherapy current gastric cancer prior diagnosis malignancy cure surgery alone less 5 year study entry previous use nonhumanized monoclonal mouse rat antibody treatment another investigational product study last 30 day prior study start presence distant metastasis presence constant immunosuppressive therapy history pancreas resection ( also partial ) thoracotomy presence acute chronic systemic infection patient bowel obstruction within last 30 day know contraindication plan ECX chemotherapeutics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>gastric cancer</keyword>
	<keyword>catumaxomab</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>phase II</keyword>
	<keyword>interoperative</keyword>
	<keyword>trifunctional antibody</keyword>
</DOC>